Filing Details
- Accession Number:
- 0001140361-12-045579
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-11-05 13:48:36
- Reporting Period:
- 2012-11-01
- Filing Date:
- 2012-11-05
- Accepted Time:
- 2012-11-05 13:48:36
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
874716 | Idexx Laboratories Inc | IDXX | In Vitro & In Vivo Diagnostic Substances (2835) | 010393723 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1377232 | Phd J Michael Williams | One Idexx Drive Westbrook ME 04092 | Executive Vice President | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2012-11-01 | 2,806 | $28.66 | 10,402 | No | 4 | M | Direct | |
Common Stock | Disposition | 2012-11-01 | 2,806 | $96.02 | 7,596 | No | 4 | S | Direct | |
Common Stock | Disposition | 2012-11-01 | 131 | $96.00 | 7,465 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2012-11-01 | 2,806 | $0.00 | 2,806 | $28.66 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2015-02-02 | No | 4 | M | Direct |
Footnotes
- Includes 57 shares and 51 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on 06/30/2012 and 09/30/2012, respectively.
- The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $96.00 to $96.09, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
- Grant of options to buy shares of common stock becomes exercisable as to 2,720 shares on 02/03/2006, 2,720 on 02/03/2007, 2,720 on 02/03/2008, and the remaining 1,646 shares on 02/03/2009.